The naturally occurring endogenous class of lipid-signaling molecules, N-acyl fatty acid amides (FAAs) constitutes a large family of structurally diverse, biologically active molecules across a range of species. Numerous FAAs have been identified in bone tissue and are suggested to play a role in modulating skeletal remodeling and bone mass. With aging, remodeling leans toward negative bone balance, which initially manifests as progression into osteopenia, then osteoporosis, and carries an increasing risk of fracture over time.

As we age, there is a natural decrease in bone formation relative to resorption. The discovery that Oleoyl Serine is an endogenous lipid regulator of bone remodeling with a unique dual mechanism of action favoring bone formation is innovative as compared to the currently marketed products. 

Our compounds are naturally derived and bio-mimetic - they activate the body’s own system for modulating bone health. 

Oleic acid and serine are found on the FDA's Generally Recognized As Safe (GRAS) list. Therefore, there is reason to believe the Beryl compounds will be devoid of long-term safety risks vs. alternatives (e.g., bisphosphonates, and others, most of which require a drug holiday.

Half of Americans over age 50 will fall into osteopenia, a precursor to osteoporosis. Osteopenia is not considered a disease by the FDA even though it affects 34 million patients in the US. Physicians are reticent to treat osteopenia with medication because of the safety profile of current osteoporosis drugs. The cost/benefit analysis leaves many patients totally untreated or under treated until the severity of their disease puts them at high risk for bone breaks. Some people self-administer calcium and Vitamin D. Stabilizing bone for patients with osteopenia creates options for intellectual property and significant market opportunities for Beryl compounds.